Close this search box.
Subscriber Log In

Knowledge and Insights: The Power of Real-World Data


Buzzwords in the life sciences industry – there are many: Artificial Intelligence (AI), Gen AI, Machine Learning (ML), digital health, and real-world data (RWD)/real world evidence (RWE). All are vast, complex areas with notable potential to impact our clients and the industry overall – across the continuum of the product lifecycle, spanning clinical and commercial […]

2024 Preview: Are We There Yet?


After a year in which investor sentiment went from bad to worse, 2024 has started on a more positive note. Last week’s JP Morgan conference saw a flurry of partnership and acquisition announcements, building on the last couple of weeks of December which saw 2023’s deal making end with a bang. If the end is […]

In Case You Missed It: Three Things We Learned in Our CDMO Webinar


If you missed it, the recording is available here. If you’re short on time, here are three of the key points that I took away from the session. Our speakers included Amanda Micklus from the Norstella consulting team, and Vince Spurr, one of our CDMO experts. Perhaps more importantly, we were joined by Matt Hewitt […]

In Sickness and in Health: The CDMO/Pharma Relationship


There are two inflection points where a pharma or biotech company looks to a CDMO. In one instance, it’s a technology transfer to create regional or incremental capacity, helping reduce the risk of a single-source manufacturing process. While this isn’t risk-free, it’s relatively straightforward. In recent years, though, we’ve seen an increase in companies seeking […]

Themes from BIO Europe


There’s far too much to share in one blog post, but there were three areas that I wanted to summarise as I think they’re a good indicator of the current state of the biopharma market and give us an insight into what we can expect from pharma and biotech in 2024. 1. Dealmaking Increasing competition […]

Meet the Evaluate Team: Alex Bour


Alex Bour leads Evaluate’s Competitive Intelligence consulting practice, working closely with clients to help them to understand the nuances of their competitive environment and helping them to craft effective strategies. When you don’t find him knee-deep in Evaluate data, or pondering the latest in gene and cell therapy, you might discover him in the kitchen […]

Quick View: Biopharma Dealmaking in Q3


The first half of the year showed some promise. Did the third quarter continue the trend? Well… If you read our round up of the state of the biopharma market at the halfway point of the year, you may have come away with, if not a spring in your step, then a least a little […]

Meet the Evaluate Team: Jim Chuck


Over four years into his Evaluate career, we thought it was time to find out a little more about Jim Chuck, one of our sales leaders who helps ensure that our clients find value in our solutions. He’s been working with and leading commercial functions for over 20 years and as well as being extremely […]

CI Meets AI at Pharma CI


Last month saw many of the world’s leading pharma and biotech companies deploy their competitive intelligence (CI) specialists to Newark. Specifically, to the Pharma CI Conference and Exhibition that took place on 20th and 21st of September. I joined them, and it was one of the best iterations of the conference that I’ve been to […]

In Case You Missed It: Three Things We Learned In Our World Preview Webinar


You may have read the report, you may have pondered the infographic, but the best way to really get under the skin of the Evaluate World Preview report is to join the webinar. As well as sharing the highlights of the data from the report, the webinar gave our presenters a chance to really discuss […]